Blockade of the renin-angiotensin-aldosterone system has been established over a 25-year period as the cornerstone of therapy for patients with systolic heart failure.
This review provides a historical overview of the discovery and overwhelming evidence supporting RAAS blockade as the cornerstone of therapy for systolic heart failure.
We will shortly celebrate the 25th anniversary of the publication of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS), a clinical trial which revolutionized the treatment of heart failure and highlighted the importance of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of heart failure (Figure 1). In this article I will give a brief, historical overview of this exciting quarter-century of discovery related to the RAAS. My focus is on the treatment of heart failure in patients with a low left ventricular ejection fraction.
John J.V. McMurray (Thu,) conducted a review in Systolic Heart Failure. Renin-Angiotensin-Aldosterone System (RAAS) blockade was evaluated. Blockade of the renin-angiotensin-aldosterone system has been established over a 25-year period as the cornerstone of therapy for patients with systolic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: